|D058186||Acute Kidney Injury NIH||0.21|
|D014947||Wounds and Injuries NIH||0.18|
There is one clinical trial.
The study objectives were to assess 1/the immune status of healthcare professionals with suggestive symptomatology of Covid-19 infection and 2/the sensitivity and specificity of AAZ rapid test by comparing it with a serological ELISA test. An open-label, monocentric, prospective, non-randomized study, is conducted, including 50 hospital healthcare professionals and 50 private health professionals. Knowledge of serostatus will achieve the implementation of a strategy of management of patients according to specific immunity of health professionals
Description: Comparative study with Elisa TestMeasure: To assess the predictive value of Covid-19 rapid test Time: One week
Description: Performance evaluation of rapid tests according to the samples usedMeasure: Compare the results of rapid tests on serum and capillary samples Time: one week
Description: Use of rapid testMeasure: A posteriori diagnosis of a covid-19 recent infection with suggestive symptomatology Time: one week
Description: Analysis of clinical dataMeasure: Analysis of factors associated with negativity of PCR test on oropharyngeal swabs and positive serology Time: One week
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports